Machine learning used to estimate when brain shrinkage begins
Brain atrophy (shrinkage) in people with multiple sclerosis (MS) begins on average more than five years before disease…
Articles by Marisa Wexler, MS
ECTRIMS 2023: Foralumab seen to ease brain inflammation in SPMS
Six months of treatment with foralumab, administered into the nose, led to decreases in microglial activity in five of six…
ECTRIMS 2023: New research may help explain EBV and MS link
New research by scientists in Austria may shed light on the link between the Epstein-Barr virus (EBV) and multiple sclerosis…
ECTRIMS 2023: Blood biomarker may help to predict disability in MS
Blood levels of neurofilament light chain (NfL), a marker of nerve damage, were seen to increase about a year or…
ECTRIMS 2023: Early high-efficacy treatment helps to slow disability in pediatric-onset MS
Use of high-efficacy therapies can lower the risk of disability progression in people with childhood-onset multiple sclerosis (MS), particularly…
ECTRIMS 2023: Fenebrutinib lowers new lesions in relapsing MS
Treatment with the investigational therapy fenebrutinib significantly reduced the number of new inflammatory lesions visible on MRI scans in…
ECTRIMS 2023: More disease activity when treatment stopped
A clinical trial that was testing if treatments for multiple sclerosis (MS) could be discontinued in people with stable…
ECTRIMS 2023: Personalized dosing of Tysabri shows good efficacy
A personalized dosing schedule for Tysabri (natalizumab) that aims to maintain blood levels of the drug above a certain…
ECTRIMS 2023: Treating SPMS with OCH shows promise in small study
Five of six people with secondary progressive multiple sclerosis (SPMS) treated with an experimental oral therapy called OCH saw…
ECTRIMS 2023: Under-the-skin Ocrevus found to be powerful in MS
A new under-the-skin formulation of Ocrevus (ocrelizumab) — administered in 10 minutes — is at least as effective as…
ECTRIMS 2023: EBV may trigger attack on brain protein ANO2
Infection with the Epstein-Barr virus (EBV) may prime the immune system to accidentally attack a brain protein called ANO2,…
ECTRIMS 2023: Vidofludimus calcium lowers RRMS nerve damage
Six months of treatment with the experimental oral therapy vidofludimus calcium (IMU-838) led to significant reductions in a marker…
Progression without relapses drives most disability worsening in MS
Most disability worsening events happen independent of relapse activity across all types of multiple sclerosis (MS), including clinically…
Sexual dysfunction in MS occurs at similar rates in all age groups
Problems with sexual dysfunction are a concern for multiple sclerosis (MS) patients of all ages, but the issues tend…
MS patients in UK less likely to be on treatment, new study shows
People with multiple sclerosis (MS) in the United Kingdom are less likely to be on disease-modifying treatments (DMTs)…
Viral protein blocks myelin repair, activates inflammation in models
The expression of a viral protein known as W-Env leads to the inflammatory activation of brain cells and impairs myelin…
Most disability worsening on Ocrevus not tied to relapses: Study
Among multiple sclerosis (MS) patients treated with Ocrevus (ocrelizumab), most of the disability worsening they experience is not…
Lemtrada controlled RRMS disease activity more than a decade
Over more than a decade of treatment with Lemtrada (alemtuzumab), relapse rates were low and about half of people…
Neurologists share treatment preferences for older adults with MS
For older adults with multiple sclerosis (MS) who have highly active disease, most neurologists recommend starting treatment with a…
MS symptoms can fluctuate with Ocrevus, but ‘wearing off’ not likely
People with multiple sclerosis (MS) under treatment with Ocrevus (ocrelizumab) commonly experience fluctuations in the severity of their…
Specific genes allow immune T-cells to infiltrate the brain, study finds
Researchers have identified nearly two dozen genes that help to control the movement of immune cells into the brain and…
Taking sugar molecule supplements may help ease inflammation in MS
Taking supplements of the sugar molecule N-acetylglucosamine, known as GlcNAc, was found to decrease markers of inflammation in people with…
‘Inverse vaccine’ approach lowers disease in MS mouse model
Note: This story was updated Sept. 15, 2023, to clarify ANK-700 was developed based on the preclinical work described in…
New method may be better at measuring disability improvement
A new statistical method could help to more accurately capture changes in disability severity for people with multiple sclerosis…
Study finds new molecular mechanism involved in myelin repair
A protein called Daam2 helps to regulate the activity of cells in the brain that make myelin, the fatty covering…
Octave’s blood test accurately captures MS disease activity: Study
A test that assesses the levels of 18 proteins in the blood and uses artificial intelligence algorithms can help to…
Is Aubagio still ethical to use as comparator in MS trials?
Noting that Aubagio (teriflunomide) continues to have “a robust impact on disability progression” in multiple sclerosis (MS) despite…
New MRI technique effectively maps myelin content in MS brains
A new system that can use MRI scans to effectively measure myelin content in brain tissue may help assess…
Diagnosing primary progressive MS difficult, despite guidelines
Diagnosing primary progressive multiple sclerosis (PPMS) can be challenging, with obstacles ranging from ruling out other disorders to differentiating between…
Memory problems in MS tied to lesions in brain’s ‘memory circuit’
The presence of lesions, or regions of damage, in a brain circuit tied to memory in stroke patients also associate…